2Yamaguchi K, Katayama H, Takashima T, et al. Prediction of severe adverse reactions to ionic and nonionic contrast media in Japan: evaluation of pretesting. A report from the Japanese Committee on the Safety of Contrast Media. Radiology, 1991, 178:363-367.
3Widmark JM. Imaging-related medications: a class overview. Proc (Bayl Univ Med Cent), 2007, 20:408-417.
4Thomsen HS, Morcos SK. Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines. Eur Badiol, 2006,16:1835-1840.
5Al Ghonaim M, Pannu N. Prevention and treatment of contrastinduced nephropathy. Tech Vase lnterv Radiol, 2006, 9:42-49.
6McCullough PA, Adam A, Becker CR, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol, 2006, 98 :SK-13K.
7McCuUough P. Outcomes of contrast-induced nephropathy: experience in patientsundergoing cardiovascular intervention. Catheter Cardiovasc lnterv, 2006, 67:335-343.
8Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrastinduced nephropathy..lAMA, 2006, 295:2765-2779.
9Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation, 2006, 113: 1799 -1806.
10Person PB, Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int Suppl, 2006 :S8-S10.
7Zhou J, Payen JF, Wilson DA, et al. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med ,2003,9:1085-1090.
8Zhou J, Lal B, Wilson DA, et aL Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med, 2003,50: 1120-1126.
9Sasayarna T, Nishihara M, Kondoh T, et al. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer,2009,125:1407-1413.
10Barajas R J, Hodgson JG, Chang JS, et al. Glioblastoma mul-tiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology,2010,254:564-576.
